Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-22-012079
Filing Date
2022-05-12
Accepted
2022-05-12 14:05:13
Documents
58
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q inbp20220331_10q.htm   iXBRL 10-Q 1102409
2 EXHIBIT 31.1 CERTIFICATION OF CO-CEOS ex_373888.htm EX-31.1 15662
3 EXHIBIT 31.2 CERTIFICATION OF CFO ex_373889.htm EX-31.2 16556
4 EXHIBIT 32.1 CERTIFICATION OF CO-CEOS PURSUANT TO 18 USC ex_373895.htm EX-32.1 8546
5 EXHIBIT 32.2 CERTIFICATION OF CFO PURSUANT TO 18 USC ex_373891.htm EX-32.2 7060
  Complete submission text file 0001437749-22-012079.txt   5410781

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inbp-20220331.xsd EX-101.SCH 45387
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inbp-20220331_cal.xml EX-101.CAL 39134
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20220331_def.xml EX-101.DEF 314300
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20220331_lab.xml EX-101.LAB 276061
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20220331_pre.xml EX-101.PRE 334490
52 EXTRACTED XBRL INSTANCE DOCUMENT inbp20220331_10q_htm.xml XML 957990
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-31668 | Film No.: 22917137
SIC: 2834 Pharmaceutical Preparations